Elevance Health, Inc.

As of June 30, 2026, Elevance Health, Inc. carries a market capitalization of 1.48T, placing it among publicly traded companies globally. Its enterprise value stands at 1.40T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Elevance Health, Inc.'s next confirmed earnings release is scheduled for January 27, 2027.

As of June 30, 2026, Elevance Health, Inc. has 216.84M shares outstanding.

As of June 30, 2026, Elevance Health, Inc. trades at a trailing price-to-earnings ratio of 17.24. The price-to-sales ratio is 0.43, and the price-to-book ratio stands at 1.89.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.40 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Elevance Health, Inc. trades at an EV/FCF ratio of 10.65, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.40T versus a market cap of 1.48T, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Elevance Health, Inc. posted a return on equity (ROE) of 11.20, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 4.00, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 8.25, useful for judging operating efficiency across full business cycles. The company generates approximately 35.54M in revenue per employee across its workforce of 98,875.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Elevance Health, Inc. recorded 15.99B in income tax expense. That works out to an effective tax rate of 15.61, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 102.42B, leaving 86.71B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on July 2, 2026, Elevance Health, Inc.'s stock has declined approximately 23.08% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Elevance Health, Inc. generated 3.51T in revenue and converted that into 86.71B in net income, yielding earnings per share of 391.14.

As of June 30, 2026, Elevance Health, Inc. holds 628.12B in cash and equivalents against 542.39B in total debt, resulting in a net debt position of 363.62B.

Elevance Health, Inc. produced 130.41B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -20.53B in capital expenditures, free cash flow totaled 109.88B - equivalent to 501.18 per share.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Elevance Health, Inc. paid dividends of 120.09 per share. The dividend payout ratio of 30.56 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.29, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.17, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Elevance Health, Inc. shareholders.

Elevance Health, Inc.'s most recent stock split took place on June 1, 2005 with a 1:2 split ratio.